These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33938071)

  • 41. Increase in allergen-specific IgE and ex vivo Th2 responses after a single bronchial challenge with house dust mite in allergic asthmatics.
    van de Pol MA; Lutter R; van Ree R; van der Zee JS
    Allergy; 2012 Jan; 67(1):67-73. PubMed ID: 21958117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
    Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
    Meteran H; Backer V
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
    [No Abstract]   [Full Text] [Related]  

  • 49. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
    O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
    Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
    Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS
    J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens.
    Huang HJ; Curin M; Banerjee S; Chen KW; Garmatiuk T; Resch-Marat Y; Carvalho-Queiroz C; Blatt K; Gafvelin G; Grönlund H; Valent P; Campana R; Focke-Tejkl M; Valenta R; Vrtala S
    Allergy; 2019 Dec; 74(12):2461-2478. PubMed ID: 31228873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Follicular helper T cells are responsible for IgE responses to Der p 1 following house dust mite sensitization in mice.
    Noble A; Zhao J
    Clin Exp Allergy; 2016 Aug; 46(8):1075-82. PubMed ID: 27138589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteinase-activated receptor-2 activation participates in allergic sensitization to house dust mite allergens in a murine model.
    Davidson CE; Asaduzzaman M; Arizmendi NG; Polley D; Wu Y; Gordon JR; Hollenberg MD; Cameron L; Vliagoftis H
    Clin Exp Allergy; 2013 Nov; 43(11):1274-85. PubMed ID: 24152160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
    Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
    J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.
    Bozek A; Ignasiak B; Filipowska B; Jarzab J
    Clin Exp Allergy; 2013 Feb; 43(2):242-8. PubMed ID: 23331565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
    Vitiello G; Maltagliati L; Rossi O
    Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber.
    Roux M; Devillier P; Yang WH; Montagut A; Abiteboul K; Viatte A; Zeldin RK
    J Allergy Clin Immunol; 2016 Aug; 138(2):451-458.e5. PubMed ID: 27289490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.